Business Wire | Aug 6, 2020 06:01AM EDT

Amneal Reports Second Quarter 2020 Financial Results

Aug. 06, 2020

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aug. 06, 2020--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the second quarter ended June 30, 2020.

"Amneal executed well against our operational and strategic goals in the second quarter and, even in the face of COVID-related headwinds, delivered strong financial results," said Chirag and Chintu Patel, Co-Chief Executive Officers. "Our commitment to execution, innovation and cost efficiency continues to drive growth across our Generics, Specialty and AvKARE segments and positions us well for the remainder of 2020 and beyond. We are extremely proud of our employees across the globe, who have demonstrated resiliency during this public health crisis and remain dedicated to our mission of bringing affordable medicines to patients."

Net revenue in the second quarter of 2020 was $465 million, an increase of 15% compared to $405 million in the second quarter of 2019, primarily due to the acquisition of 65% of AvKARE and its related entities, hereinafter referred to as "AvKARE" and growth of our Specialty segment. Net loss attributable to Amneal Pharmaceuticals, Inc. of $12 million in the second quarter compared to a net loss of $17 million in prior year period, reflects higher gross profit and lower interest expense, partially offset by higher operating expenses related to AvKARE. Diluted loss per share in the second quarter was $0.08 compared to a loss of $0.13 in the prior year period.

Adjusted EBITDA(1) in the second quarter of 2020 was $101 million, an increase of 9% compared to the prior year period, primarily due to higher gross profit partially offset by higher operating expenses. Adjusted net income(1) in the second quarter was $38 million, an increase of 42% compared to the prior year period, and primarily reflects higher adjusted EBITDA(1) and lower interest expense, partially offset by higher non-controlling interests due to the acquisition of 65% of AvKARE. Adjusted diluted EPS(1) in the second quarter was $0.13, compared to $0.09 for the prior year period.

^(1) See "Non-GAAP Financial Measures" below.

Maintaining Full Year 2020 Financial Outlook

Amneal is maintaining its previously provided 2020 guidance; operating cash flow excludes an expected $110 million cash tax refund, of which approximately $106 million was received during July 2020.

Full Year 2020 Financial Guidance

Net revenue $1,875 million - $1,975 million

Adjusted gross margin 44% - 46%

Adjusted EBITDA ^(1) $400 million - $450 million

Adjusted diluted EPS ^(2) $0.45 - $0.60

Operating cash flow $150 million - $200 million

Capital expenditures $60 million - $70 million

Weighted average diluted shares outstanding ^ Approximately 300 million(3)

^ Includes 100% of EBITDA from the AvKARE acquisition.(1)

^ Accounts for 35% non-controlling interest in AvKARE.(2)

^ Assumes the weighted average diluted shares outstanding of Class A and(3) Class B shares under the if-converted method.

Conference Call Information

Amneal will host a conference call and live webcast at 8:30 am Eastern Time on August 6, 2020 to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. To access the call through a conference line, dial (844) 746-0741 (in the U.S.) or (412) 317-5273 (international callers). A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (877) 344-7529 (in the U.S.) or (412) 317-0088 (international callers). The access code for the replay is 10145923.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit www.amneal.com.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as "may," "will," "could," "expect," "plan," "anticipate," "intend," "believe," "estimate," "assume," "continue," and similar words are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: the potential impact of the COVID-19 pandemic on our business, manufacturing, supply chain, financial results, financial condition, and planned capital expenditures and national and international economies, the risk that our goodwill may become impaired, which could adversely affect our financial condition and results of operations, the impact of global economic conditions; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; our ability to obtain exclusive marketing rights for our products; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including United States federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to FDA product approval requirements; risks related to federal regulation of arrangements between manufacturers of branded and generic products; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; the continuing trend of consolidation of certain customer groups; our reliance on certain licenses to proprietary technologies from time to time; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; our dependence on third-party agreements for a portion of our product offerings; our ability to identify and make acquisitions of or investments in complementary businesses and products on advantageous terms; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the significant amount of resources we expend on research and development; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income, adjusted net income per diluted share, adjusted gross profit, adjusted gross margin and adjusted operating income, which are intended as supplemental measures of the Company's performance that are not required by or presented in accordance with U.S. General Accepted Accounting Principles ("GAAP"). All business results presented in this release are not prepared in accordance with Article 11 of Regulation S-X. The calculation of non-GAAP adjusted diluted earnings per share assumes the conversion of all outstanding shares of Class B Common Stock to shares of Class A Common Stock.

Management uses these non-GAAP measures internally to evaluate and manage the Company's operations and to better understand its business because they facilitate a comparative assessment of the Company's operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance. The compensation committee of the Company's board of directors also uses certain of these measures to evaluate management's performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company's financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company's financial performance, results of operation and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company's GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to net income, diluted earnings per share or any other measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company's business.

The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable GAAP measures without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

A reconciliation of each non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(Unaudited; In thousands, except per share amounts)

Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Net revenue $ 464,662 $ 404,642 $ 963,195 $ 850,762

Cost of goods sold 319,666 296,381 633,244 606,124

Cost of goods sold 759 3,012 2,215 56,309 impairment charges

Gross profit 144,237 105,249 327,736 188,329

Selling, general and 80,944 67,281 158,920 151,717 administrative

Research and development 45,572 48,016 81,951 101,874

In-process research anddevelopment impairment - - 960 22,787 charges

Intellectual propertylegal development 3,550 2,511 4,820 6,677 expenses

Acquisition,transaction-related and 1,787 3,519 4,362 9,551 integration expenses

Charges related to legal 1,300 - 5,800 - matters, net

Restructuring and other 333 2,835 2,381 8,996 charges

Operating income (loss) 10,751 (18,913) 68,542 (113,273)

Other (expense) income:

Interest expense, net (36,669) (43,886) (76,568) (87,167)

Foreign exchange gain 3,466 8,311 (1,715) 2,847 (loss), net

Gain (loss) on sale ofinternational businesses, 123 (1,888) 123 6,930 net

Other income, net 571 149 1,204 1,256

Total other expense, net (32,509) (37,314) (76,956) (76,134)

Loss before income taxes (21,758) (56,227) (8,414) (189,407)

Provision for (benefit 2,186 (5,701) (105,987) (14,129) from) income taxes

Net (loss) income (23,944) (50,526) 97,573 (175,278)

Less: Net lossattributable to 11,948 33,624 5,498 110,495 non-controlling interests

Net (loss) incomeattributable to Amneal (11,996) (16,902) 103,071 (64,783) Pharmaceuticals, Inc.

Net (loss) income pershare attributable toAmneal

Pharmaceuticals, Inc.'scommon stockholders:

Class A and Class B-1 $ (0.08) $ (0.13) $ 0.70 $ (0.51) basic

Class A and Class B-1 $ (0.08) $ (0.13) $ 0.69 $ (0.51) diluted

Weighted-average common shares outstanding:

Class A and Class B-1 147,392 128,016 147,286 127,852 basic

Class A and Class B-1 147,392 128,016 148,309 127,852 diluted

Amneal Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited; In thousands)

June 30, 2020 December 31, 2019

Assets

Current assets:

Cash and cash equivalents $ 266,143 $ 151,197

Restricted cash 2,129 1,625

Trade accounts receivable, net 582,734 604,390

Inventories 443,956 381,067

Prepaid expenses and other current assets 184,748 70,164

Related party receivables 1,164 1,767

Total current assets 1,480,874 1,210,210

Property, plant and equipment, net 460,528 477,997

Goodwill 527,475 419,504

Intangible assets, net 1,423,826 1,382,753

Operating lease right-of-use assets 49,159 53,344

Operating lease right-of-use assets - related party 26,183 16,528

Financing lease right-of-use assets - related party 59,980 61,284

Other assets 28,731 44,270

Total assets $ 4,056,756 $ 3,665,890

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $ 599,489 $ 507,483

Current portion of long-term debt, net 29,756 21,479

Current portion of operating lease liabilities 12,512 11,874

Current portion of operating and financing lease 3,807 3,601 liabilities - related party

Current portion of note payable - related party 1,000 -

Related party payable - short term 8,455 5,969

Total current liabilities 655,019 550,406

Long-term debt, net 2,764,578 2,609,046

Note payable - related party 35,661 -

Operating lease liabilities 38,591 43,135

Operating lease liabilities - related party 24,478 15,469

Financing lease liabilities - related party 60,782 61,463

Related party payable - long term 479 -

Other long-term liabilities 93,772 39,583

Total long-term liabilities 3,018,341 2,768,696

Redeemable non-controlling interests 12,380 -

Total stockholders' equity 371,016 346,788

Total liabilities and stockholders' equity $ 4,056,756 $ 3,665,890

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(Unaudited; In thousands)

Six Months Ended June 30,

2020 2019

Cash flows from operating activities:

Net income (loss) $ 97,573 $ (175,278)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Depreciation and amortization 116,155 99,574

Amortization of Levothyroxine Transition Agreement - 36,393 asset

Unrealized foreign currency loss (gain) 1,251 (3,695)

Amortization of debt issuance costs and discount 4,214 3,218

Gain on sale of international businesses, net (123) (6,930)

Intangible asset impairment charges 3,175 79,096

Non-cash restructuring and asset-related charges - 1,314

Deferred tax benefit - (18,209)

Stock-based compensation 10,202 10,571

Inventory provision 34,708 50,410

Other operating charges and credits, net 4,156 3,155

Changes in assets and liabilities:

Trade accounts receivable, net 75,769 (162,954)

Inventories (33,182) (19,658)

Income taxes receivable associated with the CARES (110,069) - Act

Prepaid expenses, other current assets and other 8,772 28,614 assets

Related party receivables 633 (1,624)

Accounts payable, accrued expenses and other 15,172 (13,538) liabilities

Related party payables (139) 2,225

Net cash provided by (used in) operating activities 228,267 (87,316)

Cash flows from investing activities:

Purchases of property, plant and equipment (15,919) (29,629)

Acquisition of intangible assets (1,050) (50,000)

Acquisitions, net of cash acquired (254,000) -

Proceeds from sale of international businesses, net - 34,834 of cash sold

Net cash used in investing activities (270,969) (44,795)

Cash flows from financing activities:

Proceeds from issuance of debt 180,000 -

Payments of principal on debt, financing leases and (17,072) (13,500) other

Payments of deferred financing costs (4,102) -

Proceeds from exercise of stock options 158 1,385

Employee payroll tax withholding on restricted (557) (921) stock unit vesting

Acquisition of non-controlling interest - (3,543)

Tax distribution to non-controlling interest - (13,494)

Payments of principal on financing lease - related (530) (866) party

Net cash provided by (used in) financing activities 157,897 (30,939)

Effect of foreign exchange rate on cash 255 1,293

Net increase (decrease) in cash, cash equivalents, 115,450 (161,757) and restricted cash

Cash, cash equivalents, and restricted cash - 152,822 218,779 beginning of period

Cash, cash equivalents, and restricted cash - end $ 268,272 $ 57,022 of period

Cash and cash equivalents - end of period 266,143 54,893

Restricted cash - end of period 2,129 2,129

Cash, cash equivalents, and restricted cash - end $ 268,272 $ 57,022 of period

Amneal Pharmaceuticals, Inc.

Generics Operating Results

(Unaudited; In thousands)

Generics Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Net revenue - Generics $ 306,559 $ 335,064 $ 659,145 $ 717,541

Cost of goods sold 218,909 263,423 437,774 542,301

Cost of goods sold 759 3,012 2,215 56,309 impairment charges

Gross profit 86,891 68,629 219,156 118,931

Selling, general, and 12,802 14,379 29,425 38,527 administrative

Research and development 40,316 45,448 69,350 95,599

Charges related to legal 3,050 - 5,550 - matters

In-process research anddevelopment impairment - - 960 22,787 charges

Intellectual propertylegal development 3,550 2,511 4,815 5,632 expenses

Other operating 657 1,405 703 6,083 expenses, net

Operating income (loss) $ 26,516 $ 4,886 $ 108,353 $ (49,697)



Gross margin 28.3 % 20.5 % 33.2 % 16.6 %

Adjusted gross profit $ 108,167 $ 115,434 $ 256,546 $ 277,711 (Non-GAAP) ^(1)

Adjusted gross margin 35.3 % 34.5 % 38.9 % 38.7 %(Non-GAAP) ^(2)

Adjusted operating $ 61,835 $ 64,748 $ 164,335 $ 161,567 income (Non-GAAP)

^(1) Adjusted gross profit is calculated as net revenue less adjusted cost of goods sold.

^(2) Adjusted gross margin is calculated as adjusted gross profit divided by net revenue.

Generics net revenue was $307 million in the second quarter of 2020 compared to $335 million for the prior year period. The reclassification of Oxymorphone to the Specialty segment and divestiture of our international business in 2019 accounted for $15 million of the quarter to quarter decline. In addition, new product launches in 2019 including EluRyng (Generic NuvaRing) and Sucralfate partially offset base portfolio erosion primarily related to Levothyroxine and Diclofenac Gel generic competition.

Generics gross margin for the second quarter of 2020 was 28% compared to 20% for the prior year period. The increase primarily relates to new product launches and lower inventory related charges, partially offset by erosion and the reclassification of Oxymorphone. Generics adjusted gross margin for the second quarter of 2020 was 35% for the both the current and prior year period.

Generics operating income for the second quarter of 2020 was $27 million compared to of $5 million for the prior year period. The increase primarily reflects the increase in gross margin described above and lower SG&A as well as R&D expenses due to cost reduction initiatives and the timing of expenses in 2020 due to delayed spending as a result of COVID-19.

Generics adjusted operating income for the second quarter of 2020 was $62 million compared to $65 million for the prior year period primarily due to a reduction in Levothyroxine and Diclofenac revenue and the reclassification of Oxymorphone, partially offset by new product launches and a reduction of expenses as a result of cost saving initiatives and delayed spending as a result of COVID-19.

Amneal Pharmaceuticals, Inc.

Specialty Operating Results

(Unaudited; In thousands)

Three Months Ended Six Months EndedSpecialty June 30, June 30,

2020 2019 2020 2019

Net revenue - Specialty:

Rytary(r) $ 38,389 $ 33,000 $ 76,235 $ 61,828

Unithroid(r) 13,777 8,904 26,726 18,625

Zomig(r) 12,060 14,427 24,488 25,551

All other specialty 30,030 13,247 54,784 27,217 products

Total net revenue - 94,256 69,578 182,233 133,221 Specialty

Cost of goods sold 50,229 32,958 98,047 63,823

Gross profit 44,027 36,620 84,186 69,398

Selling, general, and 16,870 16,150 37,812 37,477 administrative

Research and development 5,256 2,568 12,601 6,275

(Gains) charges related to (1,750) - 250 - legal matters, net

Intellectual property legal - - 5 1,045 development expenses

Other operating expenses, 82 1,366 82 3,428 net

Operating income $ 23,569 $ 16,536 $ 33,436 $ 21,173



Gross margin 46.7 % 52.6 % 46.2 % 52.1 %

Adjusted gross profit $ 69,472 $ 56,780 $ 135,077 $ 109,769 (Non-GAAP) ^(1)

Adjusted gross margin 73.7 % 81.6 % 74.1 % 82.4 %(Non-GAAP) ^(2)

Adjusted operating income $ 49,798 $ 39,312 $ 89,105 $ 68,038 (Non-GAAP)

^(1) Adjusted gross profit is calculated as net revenue less adjusted cost of goods sold.

^(2) Adjusted gross margin is calculated as adjusted gross profit divided by net revenue.

Specialty net revenue was $94 million in the second quarter of 2020 compared to $70 million for the prior year period, primarily due to the reclassification of Oxymorphone to the Specialty segment during the third quarter of 2019, and higher revenue from Rytary(r) and Unithroid(r).

Specialty gross margin for the second quarter of 2020 was 47% compared to 53% for the prior year period primarily due to product sales mix and the impact of Oxymorphone which is a lower margin product.

Specialty adjusted gross margin for the second quarter of 2020 was 74% compared to 82% for the prior year period primarily due to the addition of lower margin Oxymorphone.

Specialty operating income for the second quarter of 2020 was $24 million compared to $17 million for the prior year period, primarily due to higher revenue, partially offset by higher cost of goods sold and R&D expenditures, including IPX203.

Specialty adjusted operating income for the second quarter of 2020 was $50 million compared to $39 million for the prior year period primarily due to the higher revenue.

Amneal Pharmaceuticals, Inc.

AvKARE Operating Results

(Unaudited; In thousands)

AvKARE ^(1) Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Net revenue - AvKARE ^(2) $ 63,847 $ - $ 121,817 $ -

Cost of goods sold ^(2) 50,528 - 97,423 -

Gross profit ^(2) 13,319 - 24,394 -

Selling, general, and administrative 15,647 - 26,435 -

Operating loss $ (2,328) $ - $ (2,041) $ -



Gross margin 20.9 % - % 20.0 % - %

Adjusted gross profit (Non-GAAP) ^(3) $ 13,319 $ - $ 24,394 $ -

Adjusted gross margin (Non-GAAP) ^(3) 20.9 % - % 20.0 % - %

Adjusted operating income (Non-GAAP) $ 5,682 $ - $ 12,449 $ -

^ The AvKARE segment includes the results of operations of AvKARE from(1) January 31, 2020, the date of the acquisition, to June 30, 2020.

^ AvKARE excludes net revenue, costs of goods sold and gross profit from(2) sales of Amneal products through this distribution channel. These financial results are included in the Generics segment.

^ There are no non-GAAP adjustments associated with gross profit and gross(3) margin.

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited; In thousands)

Reconciliations of Cost of Goods Sold to Adjusted Cost of Goods Sold

Generics Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Cost of goods sold $ 218,909 $ 263,423 $ 437,774 $ 542,301

Cost of goods sold 759 3,012 2,215 56,309 impairment charges

Adjusted to deduct (add):

Amortization 10,521 14,636 21,171 25,388

Inventory related charges 4,630 21,443 4,630 21,777

Acquisition and site 2,540 6,969 5,572 16,480 closure expenses ^(1)

Asset impairment charges 1,718 3,012 3,174 56,309 ^(2)

Stock-based compensation 1,085 813 2,061 1,409 expense

Amortization of upfront - - - 36,393 payment^ (4)

Other 782 (68) 782 1,024

Adjusted cost of goods $ 198,392 $ 219,630 $ 402,599 $ 439,830 sold (Non-GAAP)

Specialty Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Cost of goods sold $ 50,229 $ 32,958 $ 98,047 $ 63,823

Adjusted to deduct:

Amortization 25,445 20,160 50,891 40,371

Adjusted cost of goods sold $ 24,784 $ 12,798 $ 47,156 $ 23,452 (Non-GAAP)

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited; In thousands)

Reconciliations of Operating Income (Loss) to Adjusted Operating Income

Generics Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Operating income (loss) $ 26,516 $ 4,886 $ 108,353 $ (49,697)

Adjusted to add (deduct):

Acquisition and site closure 4,188 10,885 8,788 29,670 expenses ^(1)

Amortization 10,521 14,636 21,171 25,388

Inventory related charges 4,630 21,443 4,630 21,777

Stock-based compensation 2,219 3,875 3,877 5,373 expense

Asset impairment charges ^(2) 2,299 3,059 4,774 79,211

Restructuring and other charges 332 418 378 2,499 ^(3)

Charges related to legal 3,050 - 5,550 - matters

Amortization of upfront payment - - - 36,393 ^(4)

R&D milestone payment 6,841 5,614 6,841 9,929

Other 1,239 (68) (27) 1,024

Adjusted operating income $ 61,835 $ 64,748 $ 164,335 $ 161,567 (Non-GAAP)

Specialty Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Operating income $ 23,569 $ 16,536 $ 33,436 $ 21,173

Adjusted to add (deduct):

Amortization 25,445 20,159 50,891 40,371

Acquisition and site closure 83 2,251 83 5,806 expenses ^(1)

Stock-based compensation expense 717 366 1,326 510

Restructuring and other charges ^ - - - 178 (3)

R&D milestone payment - - 2,000 -

Other (16) - 1,369 -

Adjusted operating income $ 49,798 $ 39,312 $ 89,105 $ 68,038 (Non-GAAP)

AvKARE Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Operating loss $ (2,328) $ - $ (2,041) $ -

Adjusted to add:

Amortization 8,010 - 14,490 -

Adjusted operating income (Non-GAAP) $ 5,682 $ - $ 12,449 $ -

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited; In thousands, except per share amounts)

Reconciliation of Net (Loss) Income to Adjusted Net Income and Calculation ofAdjusted Diluted EPS

Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Net (loss) income $ (23,944) $ (50,526) $ 97,573 $ (175,278)

Adjusted to add (deduct):

Non-cash interest 1,998 1,617 3,864 3,218

GAAP Income tax 2,186 (5,701) (105,987) (14,129) expense (benefit)

Amortization 41,181 34,796 81,495 65,759

Stock-based 5,663 6,224 10,202 10,571 compensation expense

Acquisition and site 5,650 19,056 12,628 47,258 closure expenses ^(1)

Restructuring and 333 2,835 2,381 8,996 other charges ^(3)

Inventory related 5,125 21,443 5,125 21,777 charges

Charges related to 3,050 - 5,550 - legal matters ^(5)

Asset impairment 2,299 4,408 4,774 81,008 charges ^(2)

Amortization of - - - 36,393 upfront payment ^(4)

Foreign exchange (3,466) (8,311) 1,715 (2,847) (gain) loss

(Gain) loss on saleof international (123) 1,888 (123) (6,930) businesses, net ^(6)

R&D milestone 6,841 5,614 8,841 9,929 payments

Other 2,431 491 (238) 1,583

Income tax at 21% (10,969) (7,104) (27,974) (18,334)

Net incomeattributable to NCI (305) (61) (1,544) (140) not associated withour Class B shares

Adjusted net income $ 37,950 $ 26,669 $ 98,282 $ 68,834 (Non-GAAP)

Adjusted diluted EPS $ 0.13 $ 0.09 $ 0.33 $ 0.23 (Non-GAAP) ^(7)

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(Unaudited, In thousands)

Reconciliation of Net (Loss) Income to EBITDA and Adjusted EBITDA

Three Months Ended Six Months Ended June 30, June 30,

2020 2019 2020 2019

Net (loss) income $ (23,944) $ (50,526) $ 97,573 $ (175,278)

Adjusted to add (deduct):

Interest expense, net 36,669 43,886 76,568 87,167

Income tax expense 2,186 (5,701) (105,987) (14,129) (benefit)

Depreciation and 58,072 50,706 116,155 99,574 amortization

EBITDA (Non-GAAP) $ 72,983 $ 38,365 $ 184,309 $ (2,666)

Adjusted to add (deduct):

Stock-based 5,663 6,224 10,202 10,571 compensation expense

Acquisition and site 5,650 19,056 12,628 47,258 closure expenses ^(1)

Restructuring and 333 2,835 2,381 8,996 other charges ^(3)

Inventory related 5,125 21,443 5,125 21,777 charges

Charges related to 3,050 - 5,550 - legal matters ^(5)

Asset impairment 2,299 4,408 4,774 81,008 charges ^(2)

Amortization of - - - 36,393 upfront payment ^(4)

Foreign exchange (3,466) (8,311) 1,715 (2,847) (gain) loss

(Gain) loss on saleof international (123) 1,888 (123) (6,930) businesses, net ^(6)

R&D milestone 6,841 5,614 8,841 9,929 payments

Other 2,431 559 (238) 559

Adjusted EBITDA $ 100,786 $ 92,081 $ 235,164 $ 204,048 (Non-GAAP)

Amneal Pharmaceuticals, Inc.Non-GAAP Reconciliations(Unaudited; In thousands)

* Acquisition and site closure expenses for the three and six months ended June 30, 2020, include costs related to: (i) system integration associated with the combination with Impax Laboratories, LLC, (ii) integration and transaction activities associated with the acquisition of AvKARE, and (iii) the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition and site closure expenses for the three and six months ended June 30, 2019 include costs related to: (i) the planned cessation of manufacturing at our Hauppauge, NY facility and redundant employee costs and (ii) the combination with Impax and related integration including legal, investment banking, accounting and information technology. * Asset impairment charges for the three and six months ended June 30, 2020 are associated with equipment and intangible assets. Asset impairment charges for the three and six months ended June 20, 2019 are primarily associated with in-process research and development and intangible assets. * For the three months ended June 30, 2020, restructuring and other charges primarily consisted of cash severance charges associated with cost of benefits for management employees. For the six months ended June 30, 2020, restructuring and other charges primarily consisted of cash severance charges associated with cost of benefits for former senior executives and management employees. For the three and six months ended June 30, 2019, restructuring and other charges are primarily associated with cash severance associated with the cost of benefits for former senior executives and cash severance provided pursuant to our severance programs for employees at Hayward, CA and other facilities. * Amortization of upfront payment represents the amortization of the upfront payment made to Lannett in connection with our Transition Agreement for Levothyroxine. * For the three and six months ended June 30, 2020, charges related to legal matters were approximately $3 million and $6 million, respectively, for commercial legal claims in our Generics segment. * For the three and six months ended June 30, 2020, gain on the sale of international businesses, net was immaterial. For the three months ended June 30, 2019, loss on the sale of international businesses, net represents the loss from the sale of our Amneal Deutschland GmbH subsidiary, which comprised substantially all of the Company's operations in Germany. For the six months ended June 30, 2019, gain on the sale of international businesses, net represents the gain from the sale of our Creo Pharma Holding Limited subsidiary, which comprised substantially all of the Company's operations in the United Kingdom, partially offset by the loss from the sale of our Amneal Deutschland GmbH subsidiary. * For the three and six months ended June 30, 2020, utilizes weighted average diluted shares outstanding of 300,779 and 300,426, respectively, which consists of Class A shares and Class B shares under the if-converted method. For the three and six months ended June 30, 2019, utilizes weighted average diluted shares outstanding of 299,139 and 299,117, respectively, which consists of Class A & Class B shares under the if-converted method. View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005281/en/

CONTACT: Investor Relations Helen O'Donnell Solebury Trout (203) 428-3213